Shares of Cascadian Therapeutics, Inc. (NASDAQ:CASC) have been assigned an average rating of “Hold” from the six brokerages that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $7.00.

Several research firms have commented on CASC. Cantor Fitzgerald reissued a “hold” rating and set a $4.00 price target on shares of Cascadian Therapeutics in a research note on Wednesday, May 10th. Zacks Investment Research downgraded shares of Cascadian Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. Cowen and Company reissued a “buy” rating on shares of Cascadian Therapeutics in a research note on Wednesday, August 9th. ValuEngine downgraded shares of Cascadian Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Finally, BTIG Research began coverage on shares of Cascadian Therapeutics in a research note on Friday, April 21st. They set a “buy” rating on the stock.

ILLEGAL ACTIVITY WARNING: This article was reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/08/19/cascadian-therapeutics-inc-casc-receives-average-rating-of-hold-from-brokerages.html.

Shares of Cascadian Therapeutics (NASDAQ:CASC) opened at 3.56 on Friday. The firm’s 50-day moving average is $3.89 and its 200-day moving average is $4.01. The company’s market capitalization is $179.97 million. Cascadian Therapeutics has a 12-month low of $3.18 and a 12-month high of $10.98.

Cascadian Therapeutics (NASDAQ:CASC) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.06. During the same quarter in the previous year, the company earned ($1.57) earnings per share. On average, equities analysts predict that Cascadian Therapeutics will post $5.02 EPS for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of CASC. BlueCrest Capital Management Ltd acquired a new position in Cascadian Therapeutics during the first quarter valued at approximately $122,000. Bank of America Corp DE increased its position in Cascadian Therapeutics by 2,316.5% in the first quarter. Bank of America Corp DE now owns 37,528 shares of the biopharmaceutical company’s stock valued at $155,000 after buying an additional 35,975 shares during the period. Sabby Management LLC acquired a new position in Cascadian Therapeutics during the first quarter valued at approximately $669,000. Citadel Advisors LLC acquired a new position in Cascadian Therapeutics during the first quarter valued at approximately $142,000. Finally, Geode Capital Management LLC increased its position in Cascadian Therapeutics by 118.8% in the first quarter. Geode Capital Management LLC now owns 252,934 shares of the biopharmaceutical company’s stock valued at $1,047,000 after buying an additional 137,350 shares during the period. 83.86% of the stock is currently owned by hedge funds and other institutional investors.

Cascadian Therapeutics Company Profile

Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.

Receive News & Ratings for Cascadian Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.